Zenas BioPharma ( ZBIO ) priced an underwritten dual offering—$200M in 2.50% convertible senior notes due 2032 and 5M equity shares at $20 each—raising gross proceeds of $300M. The company expects ~$287.5M in net proceeds from its combined offerings, after deducting underwriting fees and related expenses. The underwriters have a 30-day option to purchase up to an additional $30M in convertible not...
Zenas BioPharma ( ZBIO ) priced an underwritten dual offering—$200M in 2.50% convertible senior notes due 2032 and 5M equity shares at $20 each—raising gross proceeds of $300M. The company expects ~$287.5M in net proceeds from its combined offerings, after deducting underwriting fees and related expenses. The underwriters have a 30-day option to purchase up to an additional $30M in convertible notes and 750K equity shares, on the same terms, to cover overallotments. This dual offering is expected to close on March 31, 2026. More on Zenas BioPharma, Inc. Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor Zenas BioPharma announces concurrent public offerings of convertible senior notes and common stock Zenas BioPharma, Inc. GAAP EPS of -$4.54 misses by $3.66 Seeking Alpha’s Quant Rating on Zenas BioPharma, Inc.
rawintanpin/iStock via Getty Images The following segment was excerpted from Columbia Select Mid Cap Growth Fund Q4 2025 Commentary The tepid returns for mid-cap equities came despite better-than-expected economic growth, robust corporate earnings results, and inflation that largely remained below an annualized rate of 3%. The U.S. Federal Reserve continued to ease policy, cutting rates by a quart...
rawintanpin/iStock via Getty Images The following segment was excerpted from Columbia Select Mid Cap Growth Fund Q4 2025 Commentary The tepid returns for mid-cap equities came despite better-than-expected economic growth, robust corporate earnings results, and inflation that largely remained below an annualized rate of 3%. The U.S. Federal Reserve continued to ease policy, cutting rates by a quarter point at its meetings in October and December and announcing an end to the multi-year effort to reduce the size of its balance sheet. Stocks also remained supported by ongoing excitement surrounding the artificial intelligence theme, albeit with a brief stretch of concern in November that AI-related equities were in a "bubble." Within the mid-cap universe, growth and value stocks returned -3.70% and 1.42%, as gauged by the Russell Midcap Growth and Russell Midcap Value indices, respectively. Top holdings (% of net assets): as of December 31, 2025 Take-Two Interactive Software ( TTWO ) 3.06 Carpenter Technology ( CRS ) 2.95 Howmet Aerospace ( HWM ) 2.89 Mongodb ( MDB ) 2.85 Spotify Technology ( SPOT ) 2.76 Doordash ( DASH ) 2.70 Celsius Holdings ( CELH ) 2.52 RBC Bearings ( RBC ) 2.43 Sharkninja ( SN ) 2.31 DraftKings-CI A ( DKNG ) 2.29 Top holdings exclude short-term holdings and cash, if applicable. Fund holdings are as of the date given, are subject to change at any time, and are not recommendations to buy or sell any security. Click to enlarge Quarterly portfolio recap Contributors to relative performance Carpenter Technology is a metallurgical company that produces superalloys used in the “hot” sections of aircraft engines. The stock advanced on record quarterly profitability, strong free-cash-flow generation and confident fiscal year 2026 guidance, supported by robust demand within the aerospace and power-generation markets. Carpenter posted earnings beats and raised guidance throughout 2025, which was the most profitable year in its history. The company remains pos...
If a little is good, a lot must be better, right? That may be true of knowledge, laughter, and friends, but it's not true of delaying Social Security. There are at least three good reasons waiting past age 70 to claim Social Security isn't in your best interest. Image source: Getty Images. You've undoubtedly heard that postponing Social Security until age 70 is the best way to maximize your monthl...
If a little is good, a lot must be better, right? That may be true of knowledge, laughter, and friends, but it's not true of delaying Social Security. There are at least three good reasons waiting past age 70 to claim Social Security isn't in your best interest. Image source: Getty Images. You've undoubtedly heard that postponing Social Security until age 70 is the best way to maximize your monthly benefits . For most people, full retirement age (FRA) is 67 -- the age at which you'll receive 100% of your Social Security retirement benefits. For every year you delay claiming Social Security between FRA and 70, your permanent monthly benefit increases by roughly 8%. For example, if you're scheduled to receive $2,000 per month at FRA, waiting until age 70 means receiving $2,480 per month. Continue reading